Two treatments tested in Michigan Medicine clinical trials have received FDA approval, expanding options for people with precursor and relapsed multiple myeloma. In a Q&A, Rogel Cancer Center’s Matthew Pianko discusses how the therapies work and how researchers are using genetics and risk profiling to better understand disease progression.
We use cookies to ensure you get the best experience on our website. By using this site, you accept our use of cookies.